Skip to content

Vital Signs Camera Study

Vital Signs Camera Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06140433
Acronym
VSC
Enrollment
94
Registered
2023-11-20
Start date
2024-02-02
Completion date
2024-03-15
Last updated
2024-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Rate, Respiration Rate

Brief summary

This study is a single center, prospective clinical investigation which is balanced for gender, age, Body Mass Index (BMI) and skin color. Simultaneous measurements of PR and RR on study participants will be collected in conditions described in IFU and various suboptimal conditions. The study participants will be recorded with the VSC demo app (together with a compatible camera and computing hardware) and reference devices. PR and RR data to be collected by the VSC demo app, will be post-processed after the clinical investigation and compared with the reference devices. Persons who are willing to participate will be asked to provide their consent. Primary objective: • To assess the clinical safety and effectiveness of Pulse Rate (PR) and Respiration Rate (RR) measured with the VSC-MEDlib within the intended use compared to the gold-standard reference devices. Exploratory objective: • To assess the clinical safety and effectiveness of Pulse Rate and Respiration Rate measured with the VSC-MEDlib during suboptimal circumstances (outside the scope of the intended use), compared to the gold-standard reference devices.

Interventions

DEVICEVSC-MEDlib

VSC-MEDlib will be used for post-processing

Sponsors

Philips Clinical & Medical Affairs Global
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Persons with ASA I or II classification * Adult population (age \>18 years old) * BMI ≥ 18 - ≤ 40 kg/m2 * Able to intensively exercise for 10 minutes * Persons willing to give informed consent * Willingness to have vital signs measured by a medical mobile application * Willingness to follow study protocol (e.g., put on sunglasses, facial make-up, medical face-mask and sitting still up to 2 minutes)

Exclusion criteria

* Vulnerable populations (e.g., age \<18 years old, not able to consent by themselves, or immunecompromised or pregnant women) * Cardiac arrhythmias (e.g., Atrial Fibrillation, Supraventricular Tachycardia, Ventricular arrhythmia, regular ectopic beats) * Persons present signs of infection * Participant has known allergic reactions to make-up and/or make-up remover * Persons with positive COVID 19 test in last 14 days * Participant who exhibit irregular or excessive movement such as tremors, tics, shaking and/or shivering * Participant is Philips employee or their family members residing with this Philips employee.

Design outcomes

Primary

MeasureTime frameDescription
Clinical safety and effectiveness VSC-MEDlib according to IFU2 hoursClinical safety and effectiveness of the non-invasive and contactless measurement RR by the VSC-MEDlib within the intended use.

Other

MeasureTime frameDescription
Clinical safety and effectiveness VSC-MEDlib during suboptimal conditions2 hoursSafety and clinical effectiveness during suboptimal conditions, in RMSE, availability, and precision of the non-invasive and contactless measurement of RR by the VSCMEDlib.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026